On September 28, 2025, Alioth Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Alioth") announced the completion of its Series A++ financing round, raising over RMB 100 million. This round of financing was led by Lapam Capital, with participation from Guohai Innovation Capital, and Yishan Capital served as the exclusive financial advisor for this round. The financing funds will be utilized in areas such as "the research and development and industrialization of filtration membrane materials, as well as the continuous research and development and commercialization of pharmaceutical process filter products" by Alioth.

Since its inception, Alioth has secured multiple equity investments from leading domestic private equity funds, with a cumulative financing amount of several hundred million yuan. Specifically, it received Series A financing from "Matrix Partners China, Legend Capital, and Yishan Capital" in October 2022, and Series A+ financing from "AstraZeneca-CICC Fund and HJ Partners" in October 2023.

Jia Qijun, the founder and CEO of Alioth, said, "We are grateful for the high recognition from Lapam Capital and Guohai Innovation Capital and the substantial financial support of over RMB 100 million, which will help the company achieve a systematic layout of the three dimensions of the pharmaceutical filtration industry: 'independent filtration membrane materials - filtration product research, development, and production - terminal commercial applications,' and accelerate the global commercial promotion of filtration products."

One of the focuses of this strategic financing round is to establish Alioth's membrane industrialization production line. On the one hand, it will enable the production of filter key consumables - filtration membranes, enhancing independent supply capabilities and strengthening core competitiveness. On the other hand, amidst the complex and changing geopolitical influences and the reconfiguration of the global pharmaceutical industry supply chain, as well as the acceleration of domestic pharmaceutical industry localization substitution/upgrading, this is a crucial move for Alioth to seize strategic development opportunities.

Alioth will remain true to its original aspiration, adhering to the development philosophy of "innovation-driven and quality-first." It will continuously enhance product innovation capabilities, strengthen business competitive moats, persist in taking "creating value for customers" as its core business, continuously refine high-quality filtration products to meet the development needs of the industrial ecosystem, integrate resources with an "ecological thinking" approach, and provide unique "Alioth" solutions for the global pharmaceutical industry.

The project leader from Lapam Capital stated, "With the rapid development of innovative drugs, the market size of upstream filtration membrane materials in pharmaceutical processes is vast. Meanwhile, driven by factors such as cost optimization and supply chain security, there is a strong willingness to replace imported upstream consumables. Alioth possesses research and development and independent innovation capabilities in underlying core membrane materials, addressing 'bottleneck' issues. It is a rare and valuable player in the industry. Currently, relying on its excellent product performance, Alioth has gained access from several leading domestic pharmaceutical companies. Leveraging the influence and demonstration effect of these leading customers, it can rapidly enhance brand awareness and market influence. We look forward to Alioth continuously launching better and more cost-effective products, safeguarding the supply chain security of pharmaceutical enterprises, helping customers optimize drug development and production processes, and improving drug production safety, ultimately achieving rapid catch-up and surpassing in terms of brand and market share in high-end biopharmaceutical applications."

The project leader from Guohai Innovation Capital said, "China's biopharmaceutical industry is booming, and the upstream bioprocess market in the industrial chain is experiencing rapid growth. As one of the core components of biopharmaceutical processes, the membrane filtration field has strong demand, and the trend of import substitution is clear, with vast growth potential. Through independent research and development, Alioth has broken the import monopoly and built a complete product line covering filtration membrane materials, filters, and hardware systems, providing biopharmaceutical companies with high-performance and cost-effective filtration solutions. It has also entered the supply chains of several leading domestic pharmaceutical companies, achieving key market breakthroughs. We are delighted to participate in this financing round of Alioth and look forward to the company continuously launching high-performance and cost-effective product series, growing into a benchmark enterprise leading the import substitution of upstream consumables, and contributing to the self-sufficiency of China's biopharmaceutical industrial chain."

The project team from Yishan Capital said, "We sincerely welcome the new shareholders, Lapam Capital and Guohai Innovation Capital, to join the Alioth family. Yishan Capital has deeply experienced the new shareholders' investment teams' profound understanding and unique insights into the biopharmaceutical filtration track industry. We jointly witness the rise and transformation of China's emerging biopharmaceutical filtration process player and look forward to Alioth 'remaining true to its original aspiration, accelerating the research and development and commercialization of filter products, meeting the filtration process needs of domestic pharmaceutical companies while deeply deploying global markets such as Europe and the United States, and accelerating the pace of global supply of membrane materials and filtration equipment.'"